. . . "on January 21, 2016, nearly four years after publishing its proposed rule, CMS finalized the rule, which will take effect April 1, 2016.[1] The Final Rule implements changes to AMP that the ACA required, replaces the calculation methodology for AMP in the withdrawn Deficit Reduction Act (DRA) rule,[2] and provides additional rules for determining Best Price (BP) reported for innovator drugs and biological products."
'via Blog this'
Return Home: The Designated Representative and Exemptee Blog
For Designated Representative license applicants - Training programs, courses, classes, seminars:
California (earn a training affidavit):- CA Designated Representative Wholesaler Training - Available around-the-clock 24 x 7
- CA Designated Representative 3PL Training
- CA Designated Representative Reverse Distributor Training
- The Designated Representative Institute

No comments:
Post a Comment
Note: Only a member of this blog may post a comment.